文献速递神经肿瘤

单次与分次立体定向放射外科治疗大型脑膜瘤(>8 cc)的系统综述与荟萃分析

Single session versus hypofractionated stereotactic radiosurgery for large meningiomas (> 8 cc): a systematic review and meta analysis.
PubMed 文献 · J Neurooncol · 2025-11-25

该系统综述与荟萃分析比较单次立体定向放射外科(SSRS)与分次立体定向放射外科(HSRS)治疗大型脑膜瘤(>8 cc)的疗效与安全性。共纳入791个SSRS病灶和273个HSRS肿瘤,结果显示两组肿瘤控制率(95% vs. 90%)和良好临床结局率(87% vs. 85%)无显著差异,放射性周围水肿(PTE)发生率亦相似(总体7.9%)。尽管HSRS组肿瘤体积显著更大,但仍可获得与SSRS相似的结局。

要点

  • HSRS与SSRS在大型脑膜瘤的肿瘤控制和临床结局上无显著差异。
  • HSRS组肿瘤体积显著更大(17.6 cc vs. 14.6 cc),提示其可能适用于更大病灶。
  • 两组放射性周围水肿发生率相似,总体合并发生率为7.9%。

核心结论

  • 尽管HSRS组肿瘤体积显著更大,HSRS可获得与SSRS相似的结局。
  • 现有直接比较研究数据不足,需前瞻性多中心长期随访试验验证HSRS。

研究设计与样本

  • 系统综述与荟萃分析,系统检索Pubmed和Cochrane数据库纳入相关文献。
  • 共纳入791个接受SSRS的病灶和273个接受HSRS的肿瘤。

主要发现

  • 颅底肿瘤接受HSRS的比例显著高于SSRS(84.6% vs. 76%,p=0.003)。
  • HSRS组平均肿瘤体积显著大于SSRS组(17.6 cc vs. 14.6 cc,p=0.014)。
  • 合并肿瘤控制率为90%,良好临床结局率为85%,两组间无显著差异(95% vs. 90%,logit差异0.645,p=0.10;87% vs. 85%,logit差异0.26,p=0.48)。
  • 放疗后PTE总体合并发生率为7.9%,两组间无显著差异(logit差异0.03,p=0.95)。
  • SSRS组随访时间显著更长(67 vs. 49个月,p=0.037)。

临床怎么用

  • 对于大型脑膜瘤(>8 cc),HSRS可作为SSRS的替代方案,尤其适用于颅底肿瘤或体积较大者。
  • HSRS与SSRS的肿瘤控制和临床结局相似,选择时需结合病灶大小、位置及随访条件个体化决策。

局限性

  • 缺乏HSRS与SSRS直接比较研究的数据。
  • 需前瞻性多中心国际协作及长期随访研究进一步验证HSRS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: For larger meningiomas, higher radiation doses need to be delivered to the tumor, increasing the chances of radiation induced toxicity. Hypofractionated stereotactic radiosurgery (HSRS) imparts overall high dose in small multiple fractions, minimising this risk over single session SRS (SSRS). This meta analysis was conducted to homogenize the role of SRS for large meningiomas (> 8 cc) and run a comparative analysis between HSRS and SSRS. METHODOLOGY: Pubmed and Cochrane databases were systematically reviewed to include the relevant articles and meta analysis was performed to estimate pooled favorable clinical outcomes, tumor control and peritumoral edema (PTE) rates. Statistical tests were utilized to compare SSRS and HSRS modalities. RESULTS: 791 lesions underwent SSRS while 273 tumors were administered HSRS. Significantly higher percentage of Skull base tumors underwent HSRS over SSRS (84.6% vs. 76%, p = 0.003) and mean tumor size was significantly higher in the HSRS cohort (17.6 cc vs. 14.6 cc, p = 0.014). The pooled tumor control and favorable clinical outcome rates were 90% and 85% respectively, with no significant differences in HSRS and SSRS cohorts (95% vs. 90%, logit difference: 0.645, p = 0.10 and 87% vs. 85%, logit difference: 0.26, p = 0.48 respectively). Post radiosurgical PTE incidence was statistically similar for both cohorts with an overall pooled incidence of 7.9% (logit difference = 0.03, p = 0.95). Follow up period was significantly higher in patients undergoing SSRS (67 vs. 49 months, p = 0.037). CONCLUSION: Despite having significantly larger tumor volume, HSRS could achieve similar outcomes with SSRS. However, the inadequacy of data on direct comparative studies between HSRS and SSRS warrants prospective multicenter trials with international collaboration and long term follow up for HSRS. CLINICAL TRIAL NUMBER: Not applicable.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Pahwa B, Pahwa N, Sheehan JP, et al. Single session versus hypofractionated stereotactic radiosurgery for large meningiomas (> 8 cc): a systematic review and meta analysis. J Neurooncol. 2025. PMID: 41291309. doi:10.1007/s11060-025-05348-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。